Plus Therapeutics Q3 net loss $9.1M, cash $4.8M; FDA clears Phase 1 LM trial

PLUS THERAPEUTICS, INC.

2024-Q3 EPS reported -$1.67 revenue$4,412,000

Net loss YTD Sep 30, 2024: $9.1M ($1.46 basic EPS) vs $9.5M ($3.54) prior year; operating loss $10.8M vs $9.5M.
Cash and investments $4.8M at Sep 30, down from $8.6M at Dec 31, 2023; subsequent $0.9M DoD grant, $3.9M CPRIT grant expected.
FDA agreed to initiate Phase 1 multi-dose trial of Rhenium(186Re) Obisbemeda for leptomeningeal metastases (LM); enrollment starts early 2025 at 7 U.S. sites.
Completed enrollment in ReSPECT-GBM Phase 1 trial; presented positive data at CNS 2024; expanded sites to North Shore and Ohio State.
Established GMP manufacturing partnership with SpectronRx for late-stage clinical and commercial supply of Rhenium(186Re) Obisbemeda.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.